(1R,4S)-4-氨基环戊-2-烯甲酸 | 134003-04-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1R,4S)-4-氨基环戊-2-烯甲酸
• 中文别名: (1R,4S)-(+)-4-氨基环戊-2-烯甲酸
• 英文名称: (1R,4S)-4-aminocyclopenten-2-ene-1-carboxylic acid
• 英文别名: (1R,4S)-4-amino-cyclopent-2-ene carboxylic acid；(1R,4S)-(+)-4-Aminocyclopent-2-en-1-carboxylic acid；(1R,4S)-4-azaniumylcyclopent-2-ene-1-carboxylate
• CAS: 134003-04-6
• 化学式: C₆H₉NO₂
• 分子量: 127.143
• InChiKey: VTCHZFWYUPZZKL-CRCLSJGQSA-N

物化性质

• 熔点：
  180 °C
• 沸点：
  235.91°C (rough estimate)
• 密度：
  1.1931 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  29299000
• WGK Germany：
  3

SDS

Name:	(1R 4S)-4-Aminocyclopent-2-enecarboxylic Acid 95% (98% E.E.) Material Safety Data Sheet
Synonym:	None Known
CAS:	134003-04-6

Section 1 - Chemical Product MSDS Name:(1R 4S)-4-Aminocyclopent-2-enecarboxylic Acid 95% (98% E.E.) Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
134003-04-6	(1R,4S)-4-Aminocyclopent-2-enecarboxyl	95%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 134003-04-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 180 deg C (Dec.)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H9NO2
Molecular Weight: 127.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 134003-04-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1R,4S)-4-Aminocyclopent-2-enecarboxylic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 134003-04-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 134003-04-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 134003-04-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1R,4S)-4-氨基环戊-2-烯甲酸 在 palladium 10% on activated carbon 盐酸 、 氢气 、 碳酸氢钠 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 DMF (N,N-dimethyl-formamide) 、 二氯甲烷 、 水 为溶剂， 反应 172.83h， 生成 benzyl (1S,3R)-3-((diphenylmethylene)amino)cyclopentane-1-carboxylate
  参考文献：
  名称：

  [EN] TETRAHYDROPYRANYL CYCLOPENTYL 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  [FR] MODULATEURS TETRAHYDROPYRANYLE CYCLOPENTYLE DE TETRAHYDROISOQUINOLINE 1 SUBSTITUEE ET 1,1-DISUBSTITUEE DE L'ACTIVITE DES RECEPTEURS DE CHIMIOKINE

  摘要：

  公开号：

  WO2005110409A3
• 作为产物：
  描述：

  2-氮杂双环[2.2.1]庚-5-烯-3-酮 在 Rhodococcus erythropolis PR₄ amidase 作用下， 以 aq. phosphate buffer 为溶剂， 反应 1.25h， 以99%的产率得到
  参考文献：
  名称：

  来自腈水合酶途径的酰胺酶的混杂（+）-γ-内酰胺酶活性，可有效合成碳环核苷中间体

  摘要：

  根据生物信息学分析，在红球菌PR4中鉴定出酰胺酶的混杂（+）-γ-内酰胺酶活性，并发现其参与腈水合酶途径。酰胺酶具有高对映选择性，可用于文斯内酰胺的动力学拆分中。已知的结构提供了对具有绝对手性选择性的（+）-γ-内酰胺酶催化机理的罕见见解。对该内酰胺酶进行了克隆，纯化，生化表征，并证明是制备具有药用价值的碳环核苷的理想催化剂。通过分子对接和位点特异性诱变研究了该酶的手性选择性，为进一步设计这些多功能生物催化剂提供了基础。

  DOI：

  10.1016/j.bmcl.2018.02.019

文献信息

• Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
  申请人：Goble D. Stephen

  公开号：US20070238723A1

  公开（公告）日：2007-10-11

  Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

  环戊基化合物通过酰胺基团与苯并噁唑基团相连，利用苯并噁唑环的环氮原子，并进一步用杂环基团取代，这些化合物由式I表示： 用于调节CCR-2趋化因子受体，以预防或治疗炎症和免疫调节性疾病和疾病，过敏性疾病，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理病变；以及包含这些化合物的药物组合物和这些化合物和组合物的使用。
• [EN] PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST<br/>[FR] PROCEDE D'ELABORATION D'ANTAGONISTE VIS-A-VIS DU CCR-2
  申请人：MERCK & CO INC

  公开号：WO2005044795A1

  公开（公告）日：2005-05-19

  The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3- [3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro- 2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro- 4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol- 1-yl)-1-isopropylcyclopent-2- ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1, 6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)- 4-isopropyl-4-[3-(trifluoromethyl)- 7,8-dihydro-1,6-naphthyridin-6(5H)-yl] carbonyl}cyclopent-2-e n-1-yl)- 3-methoxytetrahydro-2H- pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl- 3-[3-(trifluoromethyl)-7, 8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3- methoxytetrahydro-2H-pyran-4-yl]amine.

  本发明提供了一种高效的合成方法，用于制备((1R,3S)-3-异丙基-3- [3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺及其琥珀酸盐。本发明还提供了一种高效的合成方法，用于制备中间体(3R)-3-甲氧基四氢-4H-吡喃-4-酮；(1S,4S)-4-(2,5-二甲基-1H-吡咯-1-基)-1-异丙基环戊-2-烯-1-羧酸；以及3-(三氟甲基)-5,6,7,8-四氢-1,6-萘啶；以及用于制备前体(3S,4S)-N-((1S,4S)-4-异丙基-4-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊-2-烯-1-基)-3-甲氧基四氢-2H-吡喃-4-胺。该发明还在于((1R,3S)-3-异丙基-3-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺的琥珀酸盐的优越性能。
• Catalytic Promiscuity of Ancestral Esterases and Hydroxynitrile Lyases
  作者：Titu Devamani、Alissa M. Rauwerdink、Mark Lunzer、Bryan J. Jones、Joanna L. Mooney、Maxilmilien Alaric O. Tan、Zhi-Jun Zhang、Jian-He Xu、Antony M. Dean、Romas J. Kazlauskas

  DOI：10.1021/jacs.5b12209

  日期：2016.1.27

  esterase substrates and six lyase substrates found higher catalytic promiscuity among the ancestral enzymes (P < 0.01). Ancestral esterases were more likely to catalyze a lyase reaction than modern esterases, and the ancestral HNL was more likely to catalyze ester hydrolysis than modern HNL's. One ancestral enzyme (HNL1) along the path from esterase to hydroxynitrile lyases was especially promiscuous

  催化混杂是一种有用但偶然的酶特性，因此在自然界中寻找催化混杂酶的效率很低。一些祖先的酶是新酶进化的分支点，并且被假设是混杂的。为了检验祖先酶比其现代后代更混杂的假设，我们在约 1 亿年前的酯酶分歧的羟基腈裂合酶 (HNL) 的四个分支点重建了祖先酶。两种酶类型都是α/β-水解酶折叠酶，具有相同的催化三联体，但反应类型和机制不同。酯酶通过酰基酶中间体催化水解，而裂合酶则在没有中间体的情况下催化消除。用六种酯酶底物和六种裂合酶底物筛选祖先酶及其现代后代，发现祖先酶之间具有更高的催化混杂性（P < 0.01）。祖先的酯酶比现代的酯酶更有可能催化裂合酶反应，并且祖先的HNL比现代的HNL更有可能催化酯水解。从酯酶到羟基腈裂合酶的路径中的一种祖先酶（HNL1）特别混杂，并且催化许多底物的水解和裂合酶反应。更广泛的筛选测试了未通过进化选择的机械相关反应：脱羧、迈克尔加成、γ-内酰胺水解和 1,5-二酮
• [EN] CCR-2 ANTAGONIST SALT<br/>[FR] SEL ANTAGONISTE DE CCR-2
  申请人：MERCK & CO INC

  公开号：WO2005044264A1

  公开（公告）日：2005-05-19

  The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-e n-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine.

  本发明提供了一种高效合成方法，用于制备((1R,3S)-3-异丙基-3-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺及其琥珀酸盐。本发明还提供了一种高效合成方法，用于制备中间体(3R)-3-甲氧基四氢-4H-吡喃-4-酮；(1S,4S)-4-(2,5-二甲基-1H-吡咯-1-基)-1-异丙基环戊-2-烯-1-羧酸；以及3-(三氟甲基)-5,6,7,8-四氢-1,6-萘啶；以及用于制备前体(3S,4S)-N-((1S,4S)-4-异丙基-4-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊-2-烯-1-基)-3-甲氧基四氢-2H-吡喃-4-胺。该发明还涉及((1R,3S)-3-异丙基-3-[3-(三氟甲基)-7,8-二氢-1,6-萘啶-6(5H)-基]羰基}环戊基)[(3S,4S)-3-甲氧基四氢-2H-吡喃-4-基]胺的琥珀酸盐的优越性能。
• Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
  申请人：Butora Gabor

  公开号：US20080081803A1

  公开（公告）日：2008-04-03

  The present invention is directed to compounds of the formula I: Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及以下式I的化合物： 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X、n和虚线如本文所定义，这些化合物可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。